The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Human papillomavirus testing on self‐sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs
Open accessAbstract
Women not attending cervical screening programs are at increased risk of cervical cancer. We investigated in these nonresponders to what extent offering self‐sampling devices for cervicovaginal brushes for high‐risk human papillomavirus (hrHPV) testing would induce participation and, if so, what the yield of precursor (i.e. CIN2 or worse) lesions following self‐sampling would be. In addition, we assessed screening history of participants and costs per detected high‐grade CIN2 or worse (“CIN2+”) lesion in comparison to the regular program in the Netherlands. Nonresponders received a device for hrHPV testing (self‐sampling group, n = 2,546) or an extra recall for conventional cytology (control group, n = 284). The percentage of self‐sampling responders were compared with responders in the recall group. hrHPV positive self‐sampling responders were invited for cytology and colposcopy. CIN2+ yield and costs per detected CIN2+ were evaluated. Active response was higher in the self‐sampling than in the control group (34.2 vs. 17.6%; p < 0.001). hrHPV positive self‐sampling responders were less likely to have a prior screening history than screening participants (p < 0.001), indicating that they are regular nonresponders. hrHPV prevalence was similar (8.0 vs. 6.8%; p = 0.11), but CIN2+ yield was higher in self‐sampling responders compared to screening participants (1.67 vs. 0.97%; OR = 2.93, 95% CI 1.48–5.80; p = 0.0013). Costs per CIN2+ lesion detected via self‐sampling were in the same range as those calculated for conventional cytological screening (€8,836 vs. €7,599). Offering self‐sampling for hrHPV testing in nonresponders is an attractive adjunct to effectively increase population coverage of screening without the adverse effect of markedly increased costs per detected CIN2+ lesion. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dzuba, I. G., Díaz, E. Y., Allen, B., Leonard, Y. F., Lazcano Ponce, E. C., Shah, K. V., Bishai, D., Lorincz, A., Ferris, D., Turnbull, B., et al. (2002) · Journal of Women's Health & Gender-Based Medicine · doi:10.1089/152460902753668466 · Cited by 208
Cited by
Human papillomavirus and cervical cancer
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 2,985
Fontham, E. T. H., Wolf, A. M. D., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. T., Walter, L. C., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21628 · Cited by 968
Arbyn, M., Smith, S. B., Temin, S., Sultana, F., & Castle, P. (2018) · BMJ · doi:10.1136/bmj.k4823 · Cited by 1,103
Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M.-H., Dillner, J., & Meijer, C. J. L. M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.019 · Cited by 636
Self-citationSelf-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis
Yeh, P. T., Kennedy, C. E., de Vuyst, H., & Narasimhan, M. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2018-001351 · Cited by 325
Metadata
- Authors
- Bais, A. G., van Kemenade, F. J., Berkhof, J., Verheijen, R. H. M., Snijders, P. J. F., Voorhorst, F., Babović, M., van Ballegooijen, M., Helmerhorst, T. J. M., & Meijer, C. J. L. M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-01-30
- Volume
- 120
- Issue
- 7
- Pages
- 1505-1510
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2112069821
- Cited by
- 174
- References
- 1
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.